Answers are grounded in this paper and cite their sources.
Acute myeloid leukemia (AML) is a diverse hematologic neoplasm that is distinguished by aberrant myeloid progenitor cell growth. Genetic factors, including polymorphisms in drug-metabolizing enzymes, such as CYP2B6, have been implicated in AML susceptibility and treatment outcomes. Understanding the association between CYP2B6 gene polymorphisms and AML risk can offer insights into personalized treatment strategies and prognosis.
No takes yet. Share an insight, caveat, or question.
Elderiny et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: